{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:48:00Z","timestamp":1790419680475,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministero dell\u2019Istruzione dell\u2019Universit\u00e0 e della Ricerca"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ejca.2016.11.020","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T15:10:20Z","timestamp":1482592220000},"page":"103-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients"],"prefix":"10.1016","volume":"72","author":[{"given":"Andrea","family":"Visentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Imbergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Gurrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Frezzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Trimarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8712-9656","authenticated-orcid":false,"given":"Filippo","family":"Severin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Scomazzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-5789","authenticated-orcid":false,"given":"Monica","family":"Facco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpietro","family":"Semenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2016.11.020_bib1","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2016.11.020_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2016.11.020_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2016.11.020_bib4","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.3324\/haematol.2015.126763","article-title":"Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy","volume":"100","author":"Visentin","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2016.11.020_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.14694\/EdBook_AM.2015.35.164","article-title":"Management of chronic lymphocytic leukemia","author":"Stilgenbauer","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book\/ASCO Am Soc Clin Oncol Meet"},{"key":"10.1016\/j.ejca.2016.11.020_bib6","article-title":"Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia","author":"Visentin","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ejca.2016.11.020_bib7","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2012.43.4449","article-title":"Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study","volume":"31","author":"Solomon","year":"2013","journal-title":"J Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2016.11.020_bib8","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/bjc.2011.313","article-title":"Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study","volume":"105","author":"Royle","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2016.11.020_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.beha.2010.01.004","article-title":"Autoimmune complications in chronic lymphocytic leukaemia (CLL)","volume":"23","author":"Zent","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.ejca.2016.11.020_bib10","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23785","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia","volume":"89","author":"Visco","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2016.11.020_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.23413","article-title":"Systemic amyloidosis associated with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"88","author":"Kourelis","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2016.11.020_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-208118","article-title":"Pathological fractures in a patient with chronic lymphatic leukaemia without disease progression","volume":"2015","author":"Langenberg","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ejca.2016.11.020_bib13","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.thromres.2015.05.010","article-title":"Venous thromboembolism in patients with chronic lymphocytic leukemia","volume":"136","author":"Simkovic","year":"2015","journal-title":"Thrombosis Res"},{"key":"10.1016\/j.ejca.2016.11.020_bib14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3324\/haematol.2015.136556","article-title":"Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia","volume":"101","author":"Strati","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2016.11.020_bib15","article-title":"Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia","author":"Briani","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2016.11.020_bib16","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3324\/haematol.2015.128793","article-title":"Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience","volume":"100","author":"Strati","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2016.11.020_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.ejca.2016.11.020_bib18","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.clml.2015.03.013","article-title":"Second myeloid malignancies in a large cohort of patients with chronic lymphocytic leukemia: a single institution experience","volume":"15","author":"Chavez","year":"2015","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"6","key":"10.1016\/j.ejca.2016.11.020_bib19","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/annonc\/mdw072","article-title":"Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia","volume":"27","author":"Falchi","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2016.11.020_bib20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2007.06801.x","article-title":"Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia","volume":"139","author":"Maddocks-Christianson","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2016.11.020_bib21","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer institute-working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2016.11.020_bib22","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.23979","article-title":"Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment","volume":"90","author":"Hallek","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2016.11.020_bib23","first-page":"979","article-title":"Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases","volume":"25","author":"Langerak","year":"2011","journal-title":"Leukemia Off J Leukemia Soc Am Leukemia Res Fund, UK"},{"key":"10.1016\/j.ejca.2016.11.020_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.6004\/jnccn.2015.0045","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 1.2015","volume":"13","author":"Zelenetz","year":"2015","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ejca.2016.11.020_bib25","first-page":"1458","article-title":"ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia","volume":"26","author":"Pospisilova","year":"2012","journal-title":"Leukemia Off J Leukemia Soc Am Leukemia Res Fund, UK"},{"key":"10.1016\/j.ejca.2016.11.020_bib26","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2016.11.020_bib27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.clml.2015.06.001","article-title":"Integrated CLL scoring system, a new and simple index to predict time to treatment and overall survival in patients with chronic lymphocytic leukemia","volume":"15","author":"Visentin","year":"2015","journal-title":"Clin lymphoma, myeloma & leukemia"},{"key":"10.1016\/j.ejca.2016.11.020_bib28","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1182\/blood.V126.23.5265.5265","article-title":"Disease progression and complications are the main cause of death in patients with chronic lymphocytic leukemia (CLL) independent of age and comorbidities at diagnosis","volume":"126","author":"Strati","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2016.11.020_bib29","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2008.17.5398","article-title":"Other malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma. Journal of clinical oncology","volume":"27","author":"Tsimberidou","year":"2009","journal-title":"Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2016.11.020_bib30","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.ejca.2016.11.020_bib31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.clml.2015.02.001","article-title":"Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia","volume":"15","author":"Strati","year":"2015","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.ejca.2016.11.020_bib32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/10428190500063054","article-title":"Idiopathic thrombocytopenic purpura and myasthenia gravis after fludarabine treatment for chronic lymphocytic leukemia","volume":"46","author":"Fujimaki","year":"2005","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.ejca.2016.11.020_bib33","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.3109\/10428194.2015.1137293","article-title":"Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience","volume":"57","author":"Laurenti","year":"2016","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.ejca.2016.11.020_bib34","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.leukres.2006.02.011","article-title":"Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia","volume":"30","author":"Nishida","year":"2006","journal-title":"Leukemia Res"},{"key":"10.1016\/j.ejca.2016.11.020_bib35","first-page":"346","article-title":"Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia","volume":"30","author":"Rogers","year":"2016","journal-title":"Leukemia Off J Leukemia Soc Am Leukemia Res Fund, UK"},{"key":"10.1016\/j.ejca.2016.11.020_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl J Med"},{"key":"10.1016\/j.ejca.2016.11.020_bib37","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2016.11.020_bib38","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2016.11.020_bib39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bjh.13602","article-title":"Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia","volume":"173","author":"Rider","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2016.11.020_bib40","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2016.11.020_bib41","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/cncr.30069","article-title":"Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity","volume":"122","author":"Thompson","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2016.11.020_bib42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.blre.2015.12.002","article-title":"Targeted therapies for CLL: practical issues with the changing treatment paradigm","volume":"30","author":"Jain","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.ejca.2016.11.020_bib43","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutre","year":"2015","journal-title":"Leukemia lymphoma"},{"issue":"3","key":"10.1016\/j.ejca.2016.11.020_bib44","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.14324","article-title":"Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study","volume":"175","author":"Thompson","year":"2016","journal-title":"Br J Haematol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916325989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916325989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T13:51:41Z","timestamp":1657029101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804916325989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":44,"alternative-id":["S0959804916325989"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.11.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}